First Midwest Bank Trust Division Decreases Position in Bristol-Myers Squibb Co (BMY)

First Midwest Bank Trust Division cut its holdings in shares of Bristol-Myers Squibb Co (NYSE:BMY) by 9.8% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 29,494 shares of the biopharmaceutical company’s stock after selling 3,204 shares during the period. First Midwest Bank Trust Division’s holdings in Bristol-Myers Squibb were worth $1,879,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors have also bought and sold shares of the company. First Trust Advisors LP raised its position in shares of Bristol-Myers Squibb by 10.7% in the second quarter. First Trust Advisors LP now owns 433,050 shares of the biopharmaceutical company’s stock worth $24,130,000 after acquiring an additional 41,892 shares during the period. Toronto Dominion Bank raised its position in shares of Bristol-Myers Squibb by 54.0% in the first quarter. Toronto Dominion Bank now owns 464,591 shares of the biopharmaceutical company’s stock worth $25,264,000 after acquiring an additional 162,884 shares during the period. Oppenheimer & Co. Inc. raised its position in shares of Bristol-Myers Squibb by 2.5% in the second quarter. Oppenheimer & Co. Inc. now owns 358,509 shares of the biopharmaceutical company’s stock worth $19,976,000 after acquiring an additional 8,813 shares during the period. Mutual of America Capital Management LLC raised its position in shares of Bristol-Myers Squibb by 1.9% in the first quarter. Mutual of America Capital Management LLC now owns 201,037 shares of the biopharmaceutical company’s stock worth $10,932,000 after acquiring an additional 3,833 shares during the period. Finally, Dividend Assets Capital LLC acquired a new position in shares of Bristol-Myers Squibb in the second quarter worth about $737,000. Institutional investors own 69.66% of the company’s stock.

In other Bristol-Myers Squibb news, Director Theodore R. Samuels II acquired 4,000 shares of the company’s stock in a transaction that occurred on Friday, December 15th. The stock was bought at an average price of $62.30 per share, with a total value of $249,200.00. Following the purchase, the director now owns 22,000 shares in the company, valued at $1,370,600. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Sandra Leung sold 156,582 shares of the company’s stock in a transaction dated Monday, December 4th. The shares were sold at an average price of $63.37, for a total transaction of $9,922,601.34. Following the sale, the executive vice president now directly owns 584,373 shares of the company’s stock, valued at approximately $37,031,717.01. The disclosure for this sale can be found here. 0.23% of the stock is currently owned by corporate insiders.

A number of research analysts have weighed in on BMY shares. Hilliard Lyons downgraded shares of Bristol-Myers Squibb from a “long-term buy” rating to a “neutral” rating and set a $65.00 price objective for the company. in a research report on Tuesday, September 12th. Goldman Sachs Group reiterated a “buy” rating and issued a $65.00 price objective (up previously from $62.00) on shares of Bristol-Myers Squibb in a research report on Thursday, September 7th. SunTrust Banks upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating in a research report on Monday, October 30th. Zacks Investment Research upgraded shares of Bristol-Myers Squibb from a “hold” rating to a “buy” rating and set a $68.00 price objective for the company in a research report on Wednesday, November 1st. Finally, Barclays upped their price objective on shares of Bristol-Myers Squibb from $58.00 to $65.00 and gave the stock an “equal weight” rating in a research report on Friday, October 13th. One research analyst has rated the stock with a sell rating, eleven have issued a hold rating and ten have issued a buy rating to the stock. Bristol-Myers Squibb has an average rating of “Hold” and an average price target of $64.42.

Shares of Bristol-Myers Squibb Co (NYSE:BMY) opened at $60.96 on Tuesday. The company has a market cap of $99,773.23, a PE ratio of 24.00, a PEG ratio of 2.31 and a beta of 1.18. The company has a debt-to-equity ratio of 0.47, a quick ratio of 1.46 and a current ratio of 1.59. Bristol-Myers Squibb Co has a one year low of $46.01 and a one year high of $66.10.

Bristol-Myers Squibb (NYSE:BMY) last released its earnings results on Thursday, October 26th. The biopharmaceutical company reported $0.75 EPS for the quarter, missing analysts’ consensus estimates of $0.77 by ($0.02). The company had revenue of $5.25 billion for the quarter, compared to analysts’ expectations of $5.20 billion. Bristol-Myers Squibb had a return on equity of 32.41% and a net margin of 20.56%. The firm’s revenue for the quarter was up 6.7% on a year-over-year basis. During the same period in the prior year, the firm earned $0.77 EPS. research analysts forecast that Bristol-Myers Squibb Co will post 2.99 EPS for the current fiscal year.

The firm also recently disclosed a quarterly dividend, which will be paid on Thursday, February 1st. Investors of record on Friday, January 5th will be paid a dividend of $0.40 per share. This represents a $1.60 annualized dividend and a yield of 2.62%. The ex-dividend date is Thursday, January 4th. This is a boost from Bristol-Myers Squibb’s previous quarterly dividend of $0.39. Bristol-Myers Squibb’s dividend payout ratio is currently 61.42%.

COPYRIGHT VIOLATION NOTICE: “First Midwest Bank Trust Division Decreases Position in Bristol-Myers Squibb Co (BMY)” was first reported by Community Financial News and is the sole property of of Community Financial News. If you are viewing this report on another site, it was illegally copied and reposted in violation of United States and international copyright and trademark law. The legal version of this report can be read at https://www.com-unik.info/2017/12/26/first-midwest-bank-trust-division-decreases-position-in-bristol-myers-squibb-co-bmy.html.

Bristol-Myers Squibb Company Profile

Bristol-Myers Squibb Company is engaged in the discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceutical products. The Company’s pharmaceutical products include chemically synthesized drugs, or small molecules, and products produced from biological processes called biologics.

Want to see what other hedge funds are holding BMY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Bristol-Myers Squibb Co (NYSE:BMY).

Institutional Ownership by Quarter for Bristol-Myers Squibb (NYSE:BMY)

Receive News & Ratings for Bristol-Myers Squibb Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bristol-Myers Squibb and related companies with MarketBeat.com's FREE daily email newsletter.

Comments

Leave a Reply


share news on Facebook
tweet this investment news
share on linkedin
share on StockTwits
share on Google Plus
share on reddit